Burns McClellan was founded in 1988 by Lisa Burns and is the nation’s oldest independent investor relations and communications consultancy specializing in the life sciences. Burns McClellan has conducted campaigns to support breakthrough products and product candidates in diverse disease areas (including oncology, cardiovascular disease, rare diseases, ophthalmology, CNS, immunology, autoimmune and infectious diseases), and across a variety of technology platforms (including small molecules, biologics, antibody-based approaches, cell therapy, gene therapy and other DNA/RNA technologies, and preventive and therapeutic vaccines).

The Firm has represented more than 400 of the industry’s most dynamic and innovative biopharmaceutical companies through all phases of corporate development including commercialization. Recent clients include Kite Pharma, Gilead Sciences, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Novartis, Baxter, Bayer, Human Genome Sciences, Teva Pharmaceutical, Wyeth-Ayerst, Alkermes, Cephalon, COR Therapeutics, Endo Pharmaceuticals, OSI Pharmaceuticals, Idenix, Avanir Pharmaceuticals, and SUGEN.